Do analysts recommend MJN or WEED?

Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than Cronos Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation & earnings, MJN or WEED?

Cronos Group has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group N/A N/A N/A N/A N/A Canopy Growth C$278.39M 2.13 -C$1.05B -C$1.86 N/A

Do analysts recommend CMED or WEED?

Canopy Growth has a consensus target price of C$1.97, suggesting a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable earnings and valuation, CMED or WEED?

CanniMed Therapeutics has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CanniMed Therapeutics N/A N/A N/A N/A N/A Canopy Growth C$278.39M 2.13 -C$1.05B -C$1.86 N/A

Do analysts prefer WEED or EMC?

Canopy Growth currently has a consensus price target of C$1.97, suggesting a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts clearly believe Canopy Growth is more favorable than Emblem. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Emblem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, WEED or EMC?

Emblem has lower revenue, but higher earnings than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$278.39M 2.13 -C$1.05B -C$1.86 N/A Emblem $5.71M 43.02 -$24.81M -$0.19 N/A

Do analysts prefer ICC or WEED?

Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than ICC Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ICC Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, ICC or WEED?

ICC Labs has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ICC Labs C$533.68K 419.04 C$2.35M C$0.02 95.29 Canopy Growth C$278.39M 2.13 -C$1.05B -C$1.86 N/A

Which has preferable earnings and valuation, OGI or WEED?

Organigram has higher earnings, but lower revenue than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$274.19M 0.76 -C$57.23M -C$0.21 N/A Canopy Growth C$278.39M 2.13 -C$1.05B -C$1.86 N/A

Canopy Growth (WEED) Competitors

C$1.39 -0.04 (-2.80%)

As of 01:15 PM Eastern

Compare

WEED vs. MJN, CMED, EMC, ICC, and OGI

Should you buy Canopy Growth stock or one of its competitors? MarketBeat compares Canopy Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Canopy Growth include Cronos Group (MJN), CanniMed Therapeutics (CMED), Emblem (EMC), ICC Labs (ICC), and Organigram (OGI). These companies are all part of the "cannabis" industry.

How does Canopy Growth compare to Cronos Group?

Cronos Group (CVE:MJN) and Canopy Growth (TSE:WEED) are both small-cap cannabis companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -107.39%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	N/A	N/A	N/A
Canopy Growth	-107.39%	-47.41%	-3.83%

Cronos Group has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$278.39M	2.13	-C$1.05B	-C$1.86	N/A

Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Cronos Group's average media sentiment score of 1.56 beat Canopy Growth's score of 0.71 indicating that Cronos Group is being referred to more favorably in the media.

Company	Overall Sentiment
Cronos Group	Very Positive
Canopy Growth	Positive

Summary

Canopy Growth beats Cronos Group on 6 of the 10 factors compared between the two stocks.

How does Canopy Growth compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Canopy Growth (TSE:WEED) are both small-cap cannabis companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Canopy Growth has a consensus target price of C$1.97, suggesting a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

CanniMed Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -107.39%. CanniMed Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CanniMed Therapeutics	N/A	N/A	N/A
Canopy Growth	-107.39%	-47.41%	-3.83%

In the previous week, Canopy Growth's average media sentiment score of 0.71 beat CanniMed Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
CanniMed Therapeutics	Neutral
Canopy Growth	Positive

CanniMed Therapeutics has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$278.39M	2.13	-C$1.05B	-C$1.86	N/A

Summary

Canopy Growth beats CanniMed Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Canopy Growth compare to Emblem?

Canopy Growth (TSE:WEED) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Emblem has lower revenue, but higher earnings than Canopy Growth. Emblem is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$278.39M	2.13	-C$1.05B	-C$1.86	N/A
Emblem	$5.71M	43.02	-$24.81M	-$0.19	N/A

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Emblem has a net margin of 0.00% compared to Canopy Growth's net margin of -107.39%. Emblem's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-107.39%	-47.41%	-3.83%
Emblem	N/A	N/A	N/A

Canopy Growth currently has a consensus price target of C$1.97, suggesting a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts clearly believe Canopy Growth is more favorable than Emblem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Emblem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Canopy Growth's average media sentiment score of 0.71 beat Emblem's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Positive
Emblem	Neutral

Summary

Canopy Growth beats Emblem on 8 of the 14 factors compared between the two stocks.

How does Canopy Growth compare to ICC Labs?

ICC Labs (CVE:ICC) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

ICC Labs has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICC Labs	C$533.68K	419.04	C$2.35M	C$0.02	95.29
Canopy Growth	C$278.39M	2.13	-C$1.05B	-C$1.86	N/A

4.3% of Canopy Growth shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ICC Labs has a net margin of 0.00% compared to Canopy Growth's net margin of -107.39%. ICC Labs' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICC Labs	N/A	N/A	N/A
Canopy Growth	-107.39%	-47.41%	-3.83%

In the previous week, Canopy Growth's average media sentiment score of 0.71 beat ICC Labs' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
ICC Labs	Neutral
Canopy Growth	Positive

Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 40.48%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Canopy Growth is more favorable than ICC Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICC Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

ICC Labs and Canopy Growth tied by winning 7 of the 14 factors compared between the two stocks.

How does Canopy Growth compare to Organigram?

Organigram (TSE:OGI) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Organigram presently has a consensus price target of C$3.13, indicating a potential upside of 111.15%. Canopy Growth has a consensus price target of C$1.97, indicating a potential upside of 40.48%. Given Organigram's stronger consensus rating and higher possible upside, analysts clearly believe Organigram is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Canopy Growth's average media sentiment score of 0.71 beat Organigram's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram	Neutral
Canopy Growth	Positive

Organigram has higher earnings, but lower revenue than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$274.19M	0.76	-C$57.23M	-C$0.21	N/A
Canopy Growth	C$278.39M	2.13	-C$1.05B	-C$1.86	N/A

Organigram has a beta of 1.449406, meaning that its share price is 45% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.193568, meaning that its share price is 19% more volatile than the broader market.

Organigram has a net margin of -9.19% compared to Canopy Growth's net margin of -107.39%. Organigram's return on equity of -6.83% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-9.19%	-6.83%	-5.56%
Canopy Growth	-107.39%	-47.41%	-3.83%

4.2% of Organigram shares are held by institutional investors. Comparatively, 4.3% of Canopy Growth shares are held by institutional investors. 31.3% of Organigram shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Organigram beats Canopy Growth on 8 of the 14 factors compared between the two stocks.

Get Canopy Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WEED vs. The Competition

Export

Metric	Canopy Growth	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$591.95M	C$2.37B	C$6.49B	C$12.01B
Dividend Yield	4.80%	2.95%	2.67%	6.20%
P/E Ratio	-0.75	4.91	24.65	36.68
Price / Sales	2.13	1,644.84	476.12	10.13
Price / Cash	1.63	10.18	43.05	82.29
Price / Book	0.64	10.48	10.45	4.38
Net Income	-C$1.05B	C$20.27B	C$3.56B	C$299.09M
7 Day Performance	-4.76%	-0.61%	-2.43%	-3.16%
1 Month Performance	-9.68%	6.33%	0.23%	-2.46%
1 Year Performance	-35.19%	18.19%	21.35%	39.86%

Canopy Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WEED Canopy Growth	2.4951 of 5 stars	C$1.39 -2.8%	C$1.97 +41.5%	-30.9%	C$587.72M	C$278.39M	N/A	2,700
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600	News Coverage Positive News
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
EMC Emblem	N/A	$1.88 +1.6%	N/A	+0.0%	$245.45M	$5.71M	N/A	N/A
ICC ICC Labs	N/A	C$1.62 -5.8%	N/A	+0.0%	C$223.64M	C$533.68K	95.29	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:WEED) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canopy Growth (WEED) Competitors

WEED vs. MJN, CMED, EMC, ICC, and OGI

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to CanniMed Therapeutics?

Summary

How does Canopy Growth compare to Emblem?

Summary

How does Canopy Growth compare to ICC Labs?

Summary

How does Canopy Growth compare to Organigram?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Canopy Growth (WEED) Competitors

WEED vs. MJN, CMED, EMC, ICC, and OGI

How does Canopy Growth compare to Cronos Group?

Do institutionals & insiders believe in MJN or WEED?

Is MJN or WEED more profitable?

Which has better valuation & earnings, MJN or WEED?

Do analysts recommend MJN or WEED?

Does the media refer more to MJN or WEED?

Summary

How does Canopy Growth compare to CanniMed Therapeutics?

Do analysts recommend CMED or WEED?

Is CMED or WEED more profitable?

Do institutionals and insiders have more ownership in CMED or WEED?

Does the media prefer CMED or WEED?

Which has preferable earnings and valuation, CMED or WEED?

Summary

How does Canopy Growth compare to Emblem?

Which has preferable valuation and earnings, WEED or EMC?

Do insiders and institutionals hold more shares of WEED or EMC?

Is WEED or EMC more profitable?

Do analysts prefer WEED or EMC?

Does the media favor WEED or EMC?

Summary

How does Canopy Growth compare to ICC Labs?

Which has higher valuation & earnings, ICC or WEED?

Do institutionals & insiders believe in ICC or WEED?

Is ICC or WEED more profitable?

Does the media favor ICC or WEED?

Do analysts prefer ICC or WEED?

Summary

How does Canopy Growth compare to Organigram?

Do analysts rate OGI or WEED?

Does the media favor OGI or WEED?

Which has preferable earnings and valuation, OGI or WEED?

Which has more risk and volatility, OGI or WEED?

Is OGI or WEED more profitable?

Do insiders & institutionals believe in OGI or WEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools